Payne HA - Search Results

1

Localising occult prostate cancer metastasis with advanced imaging techniques (LOCATE trial): a prospective cohort, observational diagnostic accuracy trial investigating whole-body magnetic resonance imaging in radio-recurrent prostate cancer.

Adeleke S, Latifoltojar A, Sidhu H, Galazi M, Shah TT, Clemente J, Davda R, Payne HA, Chouhan MD, Lioumi M, Chua S, Freeman A, Rodriguez-Justo M, Coolen A, Vadgama S, Morris S, Cook GJ, Bomanji J, Arya M, Chowdhury S, Wan S, Haroon A, Ng T, Ahmed HU, Punwani S. Adeleke S, et al. Among authors: payne ha. BMC Med Imaging. 2019 Nov 15;19(1):90. doi: 10.1186/s12880-019-0380-y. BMC Med Imaging. 2019. PMID: 31730466 Free PMC article. Clinical Trial.

2

Penile preservation in squamous cell carcinoma of the bulbomembranous urethra.

Christopher N, Arya M, Brown RS, Payne HA, Woodhouse CR, Ralph DJ. Christopher N, et al. Among authors: payne ha. BJU Int. 2002 Mar;89(4):464-5. doi: 10.1046/j.1464-4096.2001.00135.x. BJU Int. 2002. PMID: 11872045 No abstract available.

3

Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen (PSA) levels < 10 ng/mL: the "PSA negative" patients.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. Among authors: payne ha. Cancer. 2003 Dec 1;98(11):2362-7. doi: 10.1002/cncr.11821. Cancer. 2003. PMID: 14635070 Free article.

4

Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.

Birtle AJ, Freeman A, Masters JR, Payne HA, Harland SJ; BAUS Section of Oncology Cancer Registry. Birtle AJ, et al. Among authors: payne ha. BJU Int. 2005 Aug;96(3):303-7. doi: 10.1111/j.1464-410X.2005.05619.x. BJU Int. 2005. PMID: 16042718

5

Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy.

Arumainayagam N, Kumaar S, Ahmed HU, Moore CM, Payne H, Freeman A, Allen C, Kirkham A, Emberton M. Arumainayagam N, et al. BJU Int. 2010 Oct;106(7):991-7. doi: 10.1111/j.1464-410X.2010.09291.x. Epub 2010 Mar 9. BJU Int. 2010. PMID: 20230392

6

The evolution of antiandrogens: MDV3100 comes of age.

Dumas L, Payne H, Chowdhury S. Dumas L, et al. Expert Rev Anticancer Ther. 2012 Feb;12(2):131-3. doi: 10.1586/era.11.210. Expert Rev Anticancer Ther. 2012. PMID: 22316360 No abstract available.

7

Hormone therapy for radiorecurrent prostate cancer.

Payne H, Khan A, Chowdhury S, Davda R. Payne H, et al. World J Urol. 2013 Dec;31(6):1333-8. doi: 10.1007/s00345-012-0952-8. Epub 2012 Sep 21. World J Urol. 2013. PMID: 22996761 Review.

8

Evolution of the treatment paradigm for patients with metastatic castration-resistant prostate cancer.

Malik Z, Payne H, Ansari J, Chowdhury S, Butt M, Birtle A, Sundar S, Eswar CV, Hughes S, Bahl A. Malik Z, et al. Adv Ther. 2013 Dec;30(12):1041-66. doi: 10.1007/s12325-013-0070-z. Epub 2013 Nov 26. Adv Ther. 2013. PMID: 24276853 Review.

9

Is there an antiandrogen withdrawal syndrome with enzalutamide?

Rodriguez-Vida A, Bianchini D, Van Hemelrijck M, Hughes S, Malik Z, Powles T, Bahl A, Rudman S, Payne H, de Bono J, Chowdhury S. Rodriguez-Vida A, et al. BJU Int. 2015 Mar;115(3):373-80. doi: 10.1111/bju.12826. Epub 2014 Oct 24. BJU Int. 2015. PMID: 24906049

10

Advances in advanced prostate cancer - the continuing journey.

Payne H, Davda R, Jones R, Crabb S, Troup J, Hughes S. Payne H, et al. BJU Int. 2016 Jul;118(1):17-9. doi: 10.1111/bju.13350. Epub 2015 Nov 4. BJU Int. 2016. PMID: 26456636 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

178 results

Search Page

Filters